Aventis Pharmaceuticals Inc.

Genzyme Corporation

Liang Ma

Jeffrey Stephen Sabol

Gregory H Merriman

John L Kane, Jr

Markus Metz

Daniel Gerard McGarry

Andrew Scholte

Alexandre Gross

Mark Czekaj

Jinyu Liu

Michael Kothe

David Rampe

Patrick Shum

Garth E Ringheim

Francis A Volz

Linli Wei

Tieu-Binh Le

Barret Giese

Paul Erdman

Claude Barberis

Vinod Francis Patel

Joseph M Salvino

George C Morton

Richard F Labaudiniere

Sukanthini Thurairatnam

Matthew M Morrissette

John Ziqi Jiang

Helen J Mason

Christopher Hulme

Christopher Loren Vandeusen

Suzanne C Aldous

Jinqi Lu

Lan Mu

Marie-Pierre Cherrier

Harry Randall Munson

Patrick Wai-Kwok Shum

Daniel G Mcgarry

Alexandre 245 Eighth Street Gross

Compounds of the formula or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same. The compounds are useful as colony stimulating factor-1 receptor inhibitors ('CSF-1R inhibitors').

Colony stimulating factor-1 receptor (CSF-1R) inhibitors

Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors ('CSF-1R inhibitors').

This invention is directed to a compound of formula (I): wherein R, R, Rand Lare as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

Pyrimidine amide compounds as PGDS inhibitors

The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R, R, R, R, R, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.

Heterocyclic compounds as P2X7 ion channel blockers

A method for preparing a N-&lsqb;(aliphatic or aromatic)carbonyl)&rsqb;-2-aminoacetamide compound, and for preparing a cyclized compound therefrom, as well as novel resin bound intermediate compounds that are useful for preparing such compounds.

Methods for preparing N-&lsqb;(aliphatic or aromatic)carbonyl)&rsqb;-2-aminoaetamide compounds and for cyclizing such compounds

Growing community of inventors

Hillsborough, NJ, United States of America

Liang Ma